Skip to content
value.today

Mesoblast Limited vs Moderna, Inc.

Add a company

Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.

In short

  • Moderna, Inc. is the larger company by market value: $90.1 B against $169 M for Mesoblast Limited, 533 times as much (market caps of Jan 5, 2024 for Mesoblast Limited and Oct 30, 2026 for Moderna, Inc.). Mesoblast Limited's value is the last on file, from Jan 5, 2024: no market-data feed is connected for its exchange yet.
  • Moderna, Inc. had more revenue: $1.9 B in the year to December 2025 against $17 M for Mesoblast Limited in the year to June 2025.
  • Both made a net loss: $102 M for Mesoblast Limited and $2.8 B for Moderna, Inc.
  • Moderna, Inc. keeps more of each dollar of sales: a net margin of -145.2% against -593.8% for Mesoblast Limited.
  • Mesoblast Limited's revenue grew faster in its latest fiscal year: +191.5% against -39.9% for Moderna, Inc.
  • On the Piotroski F-score, a nine-point test of improving finances, Mesoblast Limited scores 5 and Moderna, Inc. 3.

Market value, the same start = 100

From Jan 2020: how each one's value moved, whatever its size.

0342685102713702020202120222023202420252026Mesoblast Limited 22Moderna, Inc. 1370

Revenue by fiscal year

US$ billions, as reported in each year's annual results.

$0B$5B$10B$14B$19B201720182019202020212022202320242025Mesoblast Limited $0BModerna, Inc. $2B

Side by side

Side-by-side comparison; ▲ marks the best value of a measure where higher or lower is better
MeasureMesoblast Limited
MSB.AX
Moderna, Inc.
MRNA · #275 in the world
Profile
Country🇦🇺 Australia🇺🇸 USA
SectorHealthcareHealthcare
IndustryBiotechnologyBiotechnology
Founded—2010
Size
Market cap$169 M*$90.1 B
Revenue$17 M$1.9 B
Net income$-102 M▲ best$-2.8 B
Employees—4,700
Valuation
Price to sales—35.7×
Price to book—10.4×
Free cash flow yield—-2.3%
Profitability
Gross margin70.2%▲ best55.4%
Operating margin—-158.1%
Net margin-593.8%-145.2%▲ best
Return on equity-18.9%▲ best-28.9%
Growth
Revenue growth191.5%▲ best-39.9%
Revenue growth, 3 years a year19.0%▲ best-53.4%
Financial strength
Debt to equity0.1×0.1×▲ best
Cash
Free cash flow margin-294.4%-106.2%▲ best
Shareholder returns
Shareholder yield—0.0%
Strength scores
Piotroski F-score5 of 9▲ best3 of 9
Altman Z-score zone—safe
Data as ofMarket cap Jan 2024; ratios FY2025Market cap Oct 2026; ratios FY2025

▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither

Questions and answers#

Which is bigger, Mesoblast Limited or Moderna, Inc.?

Moderna, Inc. is the larger company by market value: $90.1 B against $169 M for Mesoblast Limited, 533 times as much (market caps of Jan 5, 2024 for Mesoblast Limited and Oct 30, 2026 for Moderna, Inc.). Mesoblast Limited's value is the last on file, from Jan 5, 2024: no market-data feed is connected for its exchange yet.

Which makes more money, Mesoblast Limited or Moderna, Inc.?

Moderna, Inc. had more revenue: $1.9 B in the year to December 2025 against $17 M for Mesoblast Limited in the year to June 2025. Both made a net loss: $102 M for Mesoblast Limited and $2.8 B for Moderna, Inc.

Which is more profitable, Mesoblast Limited or Moderna, Inc.?

Moderna, Inc. keeps more of each dollar of sales: a net margin of -145.2% against -593.8% for Mesoblast Limited.

Which is growing faster, Mesoblast Limited or Moderna, Inc.?

Mesoblast Limited's revenue grew faster in its latest fiscal year: +191.5% against -39.9% for Moderna, Inc.

Which is financially stronger, Mesoblast Limited or Moderna, Inc.?

On the Piotroski F-score, a nine-point test of improving finances, Mesoblast Limited scores 5 and Moderna, Inc. 3.

Sources#

Every figure on this page comes from these, with the date shown next to it.